Treatment of influenza Relenza is indicated for treatment of both influenza A and B in adults and children (≥ 5 years) who present with symptoms typical of influenza when influenza is circulating in the community. Prevention of influenza Relenza is indicated for post-exposure prophylaxis of influenza A and B in adults and children (≥ 5 years) following contact with a clinically diagnosed case in a household (see section 5.1 for children aged 5-11 years). In exceptional circumstances, Relenza may be considered for seasonal prophylaxis of influenza A and B during a community outbreak (e.g. in case of a mismatch between circulating and vaccine strains and a pandemic situation). Relenza is not a substitute for influenza vaccination. The appropriate use of Relenza for prevention of influenza should be determined on a case-by-case basis depending on the circumstances and the population requiring protection. The use of antivirals for the treatment and prevention of influenza should take into consideration official recommendations, the variability of epidemiology, and the impact of the disease in different geographical areas and patient populations.
The Purpose of this study is to assess the efficacy and safety of three strengths of the FF/GW642444 Inhalation Powder in subject with Chronic Obstructive Pulmonary Disease (COPD)
Teva Pharmaceutical Industries Ltd., announced that the FDA approved two products for adolescent and adult patients with asthma. These products,...
The FDA has accepted for review the supplemental new drug application (sNDA) for ProAir RespiClick (albuterol sulfate) Inhalation Powder, from...
Liquidia Technologies, Inc., a wholly owned subsidiary of Liquidia Corporation announced that the FDA has issued a complete response letter (CRL) for the company’s New Drug Application (NDA) for LIQ 861 (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH).